Cara Therapeutics Inc

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    MedMen’s Territory Expansion: The Recent Agreements

    MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Why Heron Therapeutics Rose 33% in Pre-Market Trading Today

    Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.

    By Sarah Collins
  • uploads///herb _
    Company & Industry Overviews

    Curaleaf Opens Medical Marijuana Dispensary in Tallahassee

    On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

    By Mike Benson
  • uploads///cannabis _
    Company & Industry Overviews

    Cannabis Stocks Had a Mixed Performance Last Week

    Cannabis ETFs traded on a largely negative note last week.

    By Mohit Oberoi, CFA
  • uploads///hemp leaf _
    Company & Industry Overviews

    Ups and Downs in the Cannabis Space Last Week

    The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.

    By Mohit Oberoi, CFA
  • uploads///stinging nettle _
    Company & Industry Overviews

    Cannabis Updates: New Listings, Price Action, and Ratings

    The cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.

    By Mohit Oberoi, CFA
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s Top Performers: PETX Gains on Its First FDA Approval

    IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).

    By Peter Neil
  • uploads///part
    Company & Industry Overviews

    Key Cannabis Sector Updates: Analyst Ratings and Earnings

    Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.

    By Mohit Oberoi, CFA
  • uploads///part
    Earnings Report

    Charlotte’s Web Holdings Reports Record Harvest in 2018

    Charlotte’s Web Holdings (CWBHF) posted a record harvest of 675,000 pounds last year.

    By Mohit Oberoi, CFA
  • uploads///Net loss
    Company & Industry Overviews

    Analyzing CARA, INSY, and GWPH’s Earnings Trends

    GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.

    By Daniel Collins
  • uploads///brown _
    Company & Industry Overviews

    CARA, INSY, and GWPH: Analysts’ Recommendations in January

    On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.

    By Daniel Collins
  • uploads///Cara loss
    Company & Industry Overviews

    Cara Therapeutics: Earnings Trends and Recent Developments

    In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.

    By Daniel Collins
  • uploads///CARA
    Company & Industry Overviews

    Cara Therapeutics: A Financial Overview in January

    In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.

    By Daniel Collins
  • uploads///stock market pic
    Company & Industry Overviews

    Cara Therapeutics Has Risen ~18% in January

    Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.

    By Daniel Collins
  • uploads///INSY
    Company & Industry Overviews

    How Is INSYS Therapeutics Financially Positioned in January?

    In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

    By Daniel Collins
  • uploads///GW revenue
    Company & Industry Overviews

    A Look into GW Pharmaceuticals’ Revenue Trends

    In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What’s Auxly Cannabis’ MidStream Strategy in 2018?

    On August 31, Auxly Cannabis announced the completion of the acquisition of KGK Science for a total consideration of $12.3 million.

    By Margaret Patrick
  • uploads///Chart XXII
    Company & Industry Overviews

    Analyzing 22nd Century Group’s Year-to-Date Performance

    Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.

    By Mike Benson
  • uploads///Chart Insys
    Company & Industry Overviews

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

    By Mike Benson
  • uploads///seedling _
    Company & Industry Overviews

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///marijuana _
    Healthcare

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    How Is Insys Therapeutics Positioned in H2 2018?

    Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.

    By Kenneth Smith
  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///oral CR
    Company & Industry Overviews

    Cara Therapeutics’ Collaboration Agreements

    Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]

    By Kenneth Smith
  • uploads///cara pipeline Jan
    Company & Industry Overviews

    A Look at Cara Therapeutics’ Intravenous CR845

    Intravenous CR845 for pruritus Pruritus is associated with chronic conditions such as chronic kidney disease (or CKD), atopic dermatitis, eczema, cholestatic liver disease, and psoriasis. Based on CR845’s effectiveness on the peripheral nervous system and immune cells, as well as its anti-pruritic potency, Cara Therapeutics (CARA) believes the drug has the potential to treat pruritus […]

    By Kenneth Smith
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.